Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), a global pharmaceutical company, today announced the launch of its injectable semaglutide under the brand name Obeda®, marking an important step in expanding access to advanced GLP‑1 receptor agonist–based therapy for the management of type 2 diabetes in India. Dr. Reddy’s has been the first Indian company to receive Drugs Controller General of India (DCGI) approval for generic semaglutide. This launch underscores the company’s Day‑1 entry into the segment upon patent expiry,demonstrating its readiness to serve unmet patient needs in India. India faces one of the world’s largest diabetes burdens, with over 101 million adults living with thecondition, according to the ICMR‑INDIAB study. The study estimates diabetes prevalence at 11.4%,with nearly four in ten adults experiencing abdominal obesity. An additional 136 million individuals areestimated to be pre‑diabetic, placing them at high risk of developing the disease. In such a scenario,semaglutide, a GLP‑1 receptor agonist, has a globally proven track record in improving glycaemiccontrol and supporting weight management when used as part of a comprehensive treatment plan. 1In a head‑to‑head Phase III clinical study enrolling 312 participants, Dr.Reddy’s Obeda ® established non‑inferior efficacy and a safety profile comparable to the innovator drug. It showed similar glycaemic reduction. Additionally, comparable results were observed for fasting glucose control, post‑prandialglucose control, and therapeutic glycaemic response (achieving HbA1c &.0%) at the end of the study.No anti‑drug antibodies were detected, and the immunogenicity profile was similar to that of theinnovator drug 2 . With both API development and manufacturing, as well as formulation development conducted entirely in‑house, Obeda ® reflects Dr. Reddy’s strength in complex product development and peptide science. Italso showcases the company’s decade‑long expertise in peptide technology and its commitment tobringing GLP‑1 therapies to market to ensure access to high‑quality, affordable medicines andaddressing India’s evolving healthcare needs. As part of its future plans for GLP-1 therapies, thecompany will be looking at a fully integrated API and formulation approach, encompassing bothdevelopment and manufacturing in-house.Erez Israeli, Chief Executive Officer of Dr. Reddy’s, said: “Today’s launch marks a significant step in ourcommitment to expand our portfolio in critical therapeutic areas with differentiated solutions to patientsin India and across global markets. Our foray into GLP-1 therapies reflects our capabilities in complexproduct development and peptide science. It reinforces our vision to be a trusted partner in healthcareby combining innovation with access, ensuring advanced diabetes treatments are not only available butaffordable. As part of phase-1 launch, we aim to introduce generic semaglutide in several countries and,through our ‘One Product, One Quality’ approach, we are committed to ensure the same high‑qualityproduct across all markets.”M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s,said: “As the first generic semaglutide approved in the country, today’s announcement reflects ourscience‑led approach and our long‑standing efforts in expanding access to advanced therapies in India.With the country facing a rapidly rising diabetes burden, we aim to offer effective treatment options andenable more patients to benefit from globally established therapies. The launch of this important drugstrengthens our diabetes portfolio and reinforces our broader commitment to improving long‑term healthoutcomes for people living with chronic metabolic diseases. GLP‑1 therapies represent an importantarea of focus for us, and we will continue working toward building a full‑breadth portfolio for multiple. metabolic indications across all formats.”